Member Info for Nolupus

COPD interim analysis readout will show whether SNG001 is doing the job or not ..
We should know that this is not the clinical trial readout which was powered to optimise chances of success on 120 patients . Synairgen have taken a risk by showing not ´ optimum ´ results at this stage for a very good reason , imo
Why why why Richard ??

Itshendrez,

I agree that most people are here because of the COvid factor and regard COPD as accessory .
We have now arrived at the crossroads for Synairgen and therefore for our investment .
Readouts await , interim data and hospital data all in less than a month...
Who will partner with SYN to finance the rest of the journey to market ??

At the crossroads .... waiting ...

Itshendrez,

Imo , COPD should be regarded as the key result for the simple reason that no vaccin can be found for COPD but
One will eventually be found for COvid so in the long term we will be better off having good results in COPD rather than good results in covid ...
If we can double up, well that's a bonus

To all interested...
this is how things should be done , imo

Tim's antipode

https://m.youtube.com/watch?v=npEFq4AiuIY

Dallo,

In the two years here, that's the first time the erudite word has been used in connexion with my username ...
i don't think many would agree with you :-)

Chrishar,

Reality in biotechs is that most investors get out before incoming results due to large % of failures .
That does'nt mean that SYN won't get good results , it just means that investors in the sector are very wary .
The good news however is that with good results we should see a higher rise ...
Bit patience is the key word for now ...

You see RIcH , we finally agree on something :-)

But the main point of my post was not intended for you but for all the new biotech investors , I just wanted to pass on some of my very hard earned experience .

Rich,
I would'nt want to be your gran, or any other relation of yours but if you were being honest you might be inclined to agree with me , no ?

Rich,
Going back to one of the basic rules in biotech stock trading ...
Never invest more than you can afford to lose and keep your position sized in proportion to your overall portfolio ...ex 10%

When your investment is too important ( like yours was at 6-10p) what happens is that one sells out too cheaply afterwards in case of a rise or one loses a fortune in case of bad results ...

Biotech stocks are the most risky so keep this in mind .... risk / reward has to be calculated

I would be negotiating ( if good results )
A partnership deal in COPD with a major pharma to finance the P3 trial to come ...

I would give to the best partner ´ a right of first refusal ´ to SNG001 in covid 19

Thus ensuring the future of SNG and waiting on the COVid trial results which we should have in sept, imo

Covid trial result = hospital + at home results

Not in RIchard's shoes though :-)

No need for crystal balls on IMM ...

Just to be able to watch and learn with Chairman TIM ...:-)

Are your team members names Kathy and Marie ?

They must be very smart indeed ..but there is always someone smarter, I am sure ...

Andle,

Never said that news was for tommorow ..

Let's just wait and see...

We have touched my support level and k bought in anticipation ...

Takenorisk ,

IF. You believe like myself that Richard has already gotten the COPD results well you would imagine that your investment is now partly derisked or else you would have to imagine that Richard is far from being an honest man and therefore a great comedian :-)

Will have to wait and see

I am in agreement with you all,

The message was for the PI ´s

keep the Faith ...
But why ?

Why do this interview NOW ??

What was the motivation behind it ?

Andle,

One has to be contrarien with IMM trades :-)

I found it interesting that he only mentioned Gilead and not a word on last weeks news on the other English molecule

Does anyone know when this itw was done exactly ?

Well done Richard,

We have now further insight in what to expect in the near future .

Data is king so

RIchard has in all logic already got the COPD results and imv he is getting ready for the P3

In COVID he is hedging his bets whilst awaiting the data

As already mentioned , funding is the big issue and he has really said in this itw that the 14 million will not be sufficient to finish the P3 trials in COPD and COVID.

Without talking about the tone or Richard's attitude one would say that everything seems to be in place for the future and if one is reading between the lines a partnership is already in the pipe .

As a shareholder , i am awaiting the data with more confidence now than before the interview and so

Bring on the Data and bring in the partner ASAP please Richard